The INFERRCT study is a multicentre, randomised, double-blind, placebo-controlled non-commercial clinical trial.
The purpose of the INFERRCT trial is to evaluate the effect of intravenous iron carboxymaltose treatment versus placebo on cardiovascular mortality and morbidity, and quality of life in patients with myocardial infarction, and to assess the safety and tolerability of proposed treatment.
We hope that the results of our study will improve the effectiveness of cardiac diagnostic regimens, particularly among post-MI patients as a group at high risk of developing heart failure. Given that iron deficiency is a common pathology found in patients with myocardial infarction, we expect that the implementation of the proposed diagnostic algorithm in this direction and the dosage of intravenous iron preparation, will confirm the clinical and economic benefits of the proposed intervention model.
At present, clinical trials now form the basis of therapeutic and diagnostic recommendations, and we aim to obtain reliable and convincing data that can be directly translated into clinical practice and improve the health of patients at high risk of cardiovascular disease. Despite significant scientific and technological advances in medicine, cardiovascular disease resulting in myocardial infarction has been the number one cause of death in Poland for years. Specialised care during the first twelve months and monitoring of the patient’s blood iron levels may prove to be a fundamental factor in improving the distant prognosis of post-infarction patients in our country.